RxDoctor Payments Data

Cherie Sulima

Nurse Practitioner · Oak Brook, ILNPI 1457984205

Payments from drug & device makers

$844in general payments, 2019–2025

Across 14 payments — averaging $60.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$326
  • Bayer$125
  • Ardelyx, Inc.$125
  • Aurinia Pharma U.S., Inc.$120
  • Vifor Pharma, Inc.$58
  • Takeda Pharmaceuticals U.S.A., Inc.$31
  • plus $60 from 3 others

What the payments were for

  • Food & beverage$844100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$844 in reported general payments places this provider in the 80th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$138,374
Medicare patients
359
Services billed
1,154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide36$98,042
Lanthanum Carbonate40$30,430
VeltassaPatiromer Calcium Sorbitex23$25,443
Sevelamer Carbonate155$19,177
Calcium Acetate15$1,157
Bumetanide24$807
Midodrine Hcl20$623
Labetalol Hcl11$596
Hydralazine Hcl30$432
Potassium Chloride30$305
Furosemide38$255
Carvedilol14$253
Amlodipine Besylate27$204
Losartan Potassium26$190
Lisinopril21$187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$23$98,04236 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Oak Brook

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →